Latest Clinical trial Stories
VANCOUVER, British Columbia and MENLO PARK, Calif., May 28, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the company would present an abstract entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31 - June 4, 2013 in Chicago, Illinois, USA. DelMar will...
redOrbit Staff & Wire Reports - Your Universe Online More than half of the seriously disabled stroke victims participating in preliminary clinical trials of a new stem cell procedure have shown modest signs of recovery, the scientists carrying out the research reported Monday. According to Sam Marsden of The Telegraph, five out of the nine ischemic stroke patients taking part in the PISCES trial were able to regain some movement in their hands and legs after undergoing the...
Founding Registry Partners voice strong support for the shared, open-access registry able to collect data on any disease San Mateo, CA (PRWEB) May 23, 2013 PatientCrossroads today announced that the CONNECT open-access patient registry is now available for patient communities and disease organizations – including patient advocacy groups, pharmaceutical companies and medical researchers – to join. Founding Registry Partner organizations, which collectively represent 70 diseases, have...
SAN DIEGO, May 24, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the following investor conferences: Deutsche Bank Securities 38(th) Annual Health Care ConferencePresentation: May 30, 2013, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) at The Westin Boston Waterfront Hotel in Boston, Massachusetts Jefferies 2013 Global Healthcare ConferencePresentation: June 4, 2013, at 9:30...
WESTFIELD, N.J., May 23, 2013 /PRNewswire-USNewswire/ -- Stephen L. DeFelice, M.D., Founder and Chairman of FIM, The Foundation for Innovation in Medicine, released a new video criticizing mainstream health care cost projections of Medicare, Medicaid and Obamacare, among others, because they omit the discovery of cures. He cites a boom in technology, including gene modification and new organ growth as inevitable in curing many of our major costly diseases. (To view the video and...
Award presented for the poster Contact-Free Under the Mattress Monitoring for Early Recognition of End-of-Life in Med/Surg Units WALTHAM, Massachusetts, May 23, 2013 /PRNewswire/ -- EarlySense, the market leader in Proactive Patient Care Solutions(TM), announced today that the prize for 'Best Novel Idea' at the 8th Annual Rapid Response Systems and Medical Emergency Teams International Conference, hosted this year in the UK by the Royal College of Physicians, was awarded to a...
BUSAN, South Korea, May 23, 2013 /PRNewswire/ -- Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of targeted biological products for cancer, announced today a publication reporting the induction of functional anti-cancer antibodies in patients treated with the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). This...
Prospective, Multi-Center, Double-Blinded Study Confirms Prior Results in evaluating Volcano's iFR® (Instant Wave-Free Ratio(TM)) Software Modality in a Large, Real-World Population SAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary results from the ADVISE...
BioScience Laboratories, Inc. Clinical Laboratory has again exceeded market standards for Phase 1 Dermatological Safety Studies for an IND submission. Phase I Dermatological Safety Studies represent a critical transition into the human model for every IND and ANDA submission. Bozeman, MT (PRWEB) May 22, 2013 BioScience Laboratories clinical laboratory has again exceeded market standards for Phase 1 Dermatological Safety Studies for an IND submission. Twenty-two years of experience has...
RALEIGH, N.C., May 22, 2013 /PRNewswire/ -- STEPh, Inc., a full service medical communications company, is pleased to announce the launch of their web site ( http://www.stephreports.com ) dedicated to investigational drug reports [STEPh Reports]. About STEPh Reports STEPh Reports are comprehensive critical reviews of drugs in development. Each STEPh Report assesses the competitive landscape by individual drug monograph, MOA, clinical trials data, projected launch year, company,...
